Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BioChaperone insulin lispro · 2 trials · 2 indications
Incremental Area Under the Blood Glucose concentration-time Curve from 0-2 hours after the start of the meal.
Area Under the serum insulin Lispro concentration-time Curve from 0-30 minutes
| Arm | Type | Description |
|---|---|---|
| BioChaperone insulin lispro | EXPERIMENTAL | - |
| Humalog® | ACTIVE_COMPARATOR | Insulin lispro |
| Name | Type | Description |
|---|---|---|
| BioChaperone insulin lispro | DRUG | BioChaperone insulin lispro bolus infusion followed by test meal intake |
| Humalog® | DRUG | Humalog® bolus infusion followed by test meal intake |
Inclusion Criteria: * Type 1 diabetes for at least 12 months * Body Mass Index (BMI) between 18.5 and 28.5 kg/m\^2, both inclusive * Using or having used a Roche CSII system (Accu-Chek® Spirit Combo/ Accu- Chek® Spirit) for at least 6 months before screening. In Part B subjects using any form of CS...
BioChaperone insulin lispro is an investigational drug being studied for the treatment of Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus. It is a small molecule being developed by Eli Lilly and Company for use in these metabolic conditions.
BioChaperone insulin lispro is a form of insulin lispro, a rapid-acting insulin analog. It is designed to work by mimicking the body's natural insulin to help control blood sugar levels in people with diabetes. The drug is being studied for use in Type 1 and Type 2 diabetes.
BioChaperone insulin lispro is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for the treatment of Type 1 and Type 2 diabetes.
BioChaperone insulin lispro is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Type 1 and Type 2 Diabetes Mellitus.
BioChaperone insulin lispro has been studied in two completed Phase 1 clinical trials. NCT02562313 investigated continuous subcutaneous insulin infusion of a liquid formulation compared to Humalog in patients with Type 1 diabetes. NCT02562326 investigated efficacy, pharmacokinetics, safety, and tolerability compared to Humalog U-100 in patients with Type 2 diabetes.
BioChaperone insulin lispro is not the same as Humalog, but it is being studied in comparison to Humalog. BioChaperone insulin lispro is an investigational drug that combines insulin lispro with a BioChaperone technology, while Humalog is an approved insulin lispro product. The two drugs have been compared in clinical trials for diabetes treatment.